GOTHENBURG, SWEDEN / ACCESSWIRE / April 29, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, announced today that the Annual Report for 2023 is published on the company's website, www.irlab.se.
GOTHENBURG, SWEDEN / ACCESSWIRE / April 16, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, April 16, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will present at Redeye Investor Forum on April 18.
IRLAB Receives End-of-Ph 2 Meeting Confirming Alignment with the FDA
GOTHENBURG, SE / ACCESSWIRE / March 19, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 19 March 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that a scientific paper reporting the effects of IRLAB's candidate drug mesdopetam in a preclinical model of Parkinson's disease psychosis (PD-P) has been published in the journal Neurotherapeutics.
IRLAB to Present at Life Science-dagen in Gothenburg and have a Fireside Chat
GOTHENBURG, SWEDEN / ACCESSWIRE / February 28, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 28, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will present at the scientific conference Bayes@Lund 2024 on March 7, 2024.
GOTHENBURG, SWEDEN / ACCESSWIRE / February 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will present two abstracts at the scientific conference AD/PD™ 2024: 18th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Lisbon, Portugal, on March 5-9, 2024.
GOTHENBURG, SWEDEN / ACCESSWIRE / February 7, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company's year-end report for the period January-December 2022, has been published.
GOTHENBURG, SWEDEN / ACCESSWIRE / February 6, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 6, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) is a company discovering and developing novel treatments for Parkinson's disease. Pirepemat has the potential to become the first treatment for the largest unmet need in Parkinson's, prevention and reduction of falls and fall injuries, and is in the forefront of the treatment of falls in Parkinson's. The ongoing pioneering Phase IIb study, React-PD has already generated invaluable new knowledge about the specific group of recurrent fallers. Baseline fall rates show that subjects enrolled in the study fall 2-3 times more than previously anticipated, providing a higher probability to observe treatment dependent effects. Enrollment of study subjects has been ongoing at all study sites since May 2023, and the enrollment rate has stabilized. Based on the new information, IRLAB is able to more accurately predict the enrollment timelines for the remainder of the React-PD study, now anticipating that study enrollment will be completed in the third quarter 2024.
GOTHENBURG, SWEDEN / ACCESSWIRE / January 3, 2024 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, January 3, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the US FDA has granted IRLAB an end-of-Phase 2 meeting for the mesdopetam program on February 20, 2024.